Efficacy and safety of radiotherapy combined with anti‐angiogenic therapy and immune checkpoint inhibitors in MSS / pMMR metastatic colorectal cancer
Cancer Medicine · 2024
DOI: 10.1002/cam4.6820 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Menglan Zhai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors, Angiogenesis Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Society of Clinical Oncology (CSCO)-Tongshu Oncology Research Fund, CSCO-Xinda Oncology Immunotherapy Research Fund, Shanghai Cancer Prevention and Anti-Cancer Development Foundation 2020 Discovery research funding.
Abstract (Originalsprache)
Purpose
Several studies have demonstrated the effectiveness of anti‐angiogenic drugs in combination with immune checkpoint inhibitors (ICIs) in patients with microsatellite stable (MSS) or mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC). However, whether combination radiotherapy (RT) can further improve the prognosis of mCRC patients after second‐line treatment remains to be explored.
Methods
Retrospective analysis of data from mCRC patients who received anti‐angiogenic targeted therapy (TT) and immunotherapy (IT) with or without RT after the failure of standard therapy. Progression‐free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety were evaluated.
Results
A total of 82 patients who received TT + IT were analyzed. For RT group ( n = 42) versus NRT group ( n = 40), ORR was 21.4% (9/42) versus 5.0% (2/40); DCR was 83.8% (35/42) versus 65.0% (26/40). Compared with NRT group, RT improved PFS (median: 5.0 vs. 3.6 months; p = 0.04) and OS (median: 15.2 vs. 7.2 months; p = 0.01). In addition, in the population receiving RT, the PFS of RT sequential/simultaneous TT + IT was superior to TT + IT sequential RT (median: 7.1 vs. 6.2 vs. 3.5 months, p = 0.004). Multivariate analysis suggested RT was an independent prognostic factor for PFS and OS. No treatment‐related deaths were reported.
Conclusions
Compared with TT + IT, RT combined with TT + IT improved survival outcomes in MSS/pMMR mCRC patients, with manageable toxicity. RT sequential/simultaneous TT + IT treatment is expected to be the optimal strategy for MSS/PMMR mCRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Queen Mary School, Medical Department, Nanchang University, Nanchang, Jiangxi, China.
- Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, China.
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Tao Zhang, Zhenyu Lin
Förderung
- Chinese Society of Clinical Oncology (CSCO)-Tongshu Oncology Research Fund
- CSCO-Xinda Oncology Immunotherapy Research Fund
- Shanghai Cancer Prevention and Anti-Cancer Development Foundation 2020 Discovery research funding
- Wuhan Union Hospital Innovation Research
- Chinese Society of Clinical Oncology
Zitieren
APA
Zhai, M., Zhang, Z., Wang, H., Ren, J., Zhang, S., Li, M., Liu, L., Li, L., Zhang, L., Li, X., Zhang, T., & Lin, Z. (2024). Efficacy and safety of radiotherapy combined with anti‐angiogenic therapy and immune checkpoint inhibitors in MSS / pMMR metastatic colorectal cancer. Cancer Medicine. https://doi.org/10.1002/cam4.6820
Vancouver
Zhai M, Zhang Z, Wang H, Ren J, Zhang S, Li M, et al. Efficacy and safety of radiotherapy combined with anti‐angiogenic therapy and immune checkpoint inhibitors in MSS / pMMR metastatic colorectal cancer. Cancer Medicine. 2024. doi:10.1002/cam4.6820
BibTeX
@article{Zhai2024,
author = {Zhai, Menglan and Zhang, Zixuan and Wang, Haihong and Ren, Jinghua and Zhang, Sheng and Li, Mingjie and Liu, Lichao and Li, Lisha and Zhang, Lan and Li, Xin and Zhang, Tao and Lin, Zhenyu},
title = {Efficacy and safety of radiotherapy combined with anti‐angiogenic therapy and immune checkpoint inhibitors in MSS / pMMR metastatic colorectal cancer},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.6820}
}
EUVIMED